Insulin therapy for adult patients with type 2 diabetes mellitus: A position statement of the Korean diabetes association, 2017

on behalf of the Committee of Clinical Practice Guideline of Korean Diabetes Association

doi:10.4093/dmj.2017.41.5.367

Insulin therapy for adult patients with type 2 diabetes mellitus: A position statement of the Korean diabetes association, 2017

on behalf of the Committee of Clinical Practice Guideline of Korean Diabetes Association

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

Abstract

The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.

Original language	English
Pages (from-to)	367-373
Number of pages	7
Journal	Diabetes and Metabolism Journal
Volume	41
Issue number	5
DOIs	https://doi.org/10.4093/dmj.2017.41.5.367
Publication status	Published - 2017 Oct 1
Externally published	Yes

Keywords

Clinical practice guideline
Diabetes mellitus
Hypoglycemic agents
Insulin
Korea
Type 2

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4093/dmj.2017.41.5.367

Cite this

Insulin therapy for adult patients with type 2 diabetes mellitus: A position statement of the Korean diabetes association, 2017. / on behalf of the Committee of Clinical Practice Guideline of Korean Diabetes Association.
In: Diabetes and Metabolism Journal, Vol. 41, No. 5, 01.10.2017, p. 367-373.

Research output: Contribution to journal › Review article › peer-review

@article{50bb8f49eaa642bd9a2540b1efd3580a,

title = "Insulin therapy for adult patients with type 2 diabetes mellitus: A position statement of the Korean diabetes association, 2017",

abstract = "The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.",

keywords = "Clinical practice guideline, Diabetes mellitus, Hypoglycemic agents, Insulin, Korea, Type 2",

author = "{on behalf of the Committee of Clinical Practice Guideline of Korean Diabetes Association} and Lee, {Byung Wan} and Kim, {Jin Hwa} and Ko, {Seung Hyun} and Hur, {Kyu Yeon} and Kim, {Nan Hee} and Rhee, {Sang Youl} and Kim, {Hyun Jin} and Moon, {Min Kyong} and Park, {Seok O.} and Choi, {Kyung Mook} and Kim, {Tae Nyun} and Lee, {Yong Ho} and Kim, {Jin Hwa} and Hong, {Eun Gyoung} and Jaetaek Kim and Lee, {Won Young} and Bokrye Song and Kim, {Ji Young} and Yang, {Dong Hee} and {Taeyoung Yang}, Yang and {Hyeongjin Kim}, Kim",

note = "Publisher Copyright: {\textcopyright} 2017 Korean Diabetes Association.",

year = "2017",

month = oct,

day = "1",

doi = "10.4093/dmj.2017.41.5.367",

language = "English",

volume = "41",

pages = "367--373",

journal = "Diabetes and Metabolism Journal",

issn = "2233-6079",

publisher = "Korean Diabetes Association",

number = "5",

}

TY - JOUR

T1 - Insulin therapy for adult patients with type 2 diabetes mellitus

T2 - A position statement of the Korean diabetes association, 2017

AU - on behalf of the Committee of Clinical Practice Guideline of Korean Diabetes Association

AU - Lee, Byung Wan

AU - Kim, Jin Hwa

AU - Ko, Seung Hyun

AU - Hur, Kyu Yeon

AU - Kim, Nan Hee

AU - Rhee, Sang Youl

AU - Kim, Hyun Jin

AU - Moon, Min Kyong

AU - Park, Seok O.

AU - Choi, Kyung Mook

AU - Kim, Tae Nyun

AU - Lee, Yong Ho

AU - Kim, Jin Hwa

AU - Hong, Eun Gyoung

AU - Kim, Jaetaek

AU - Lee, Won Young

AU - Song, Bokrye

AU - Kim, Ji Young

AU - Yang, Dong Hee

AU - Taeyoung Yang, Yang

AU - Hyeongjin Kim, Kim

PY - 2017/10/1

Y1 - 2017/10/1

N2 - The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.

AB - The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.

KW - Clinical practice guideline

KW - Diabetes mellitus

KW - Hypoglycemic agents

KW - Insulin

KW - Korea

KW - Type 2

UR - http://www.scopus.com/inward/record.url?scp=85032590852&partnerID=8YFLogxK

U2 - 10.4093/dmj.2017.41.5.367

DO - 10.4093/dmj.2017.41.5.367

M3 - Review article

AN - SCOPUS:85032590852

SN - 2233-6079

VL - 41

SP - 367

EP - 373

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

IS - 5

ER -

Insulin therapy for adult patients with type 2 diabetes mellitus: A position statement of the Korean diabetes association, 2017

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this